Tailored low-dose gemcitabine-cisplatin combination is a feasible and effective treatment in heavily pretreated advanced breast cancer patients

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 837-837 ◽  
Author(s):  
J. E. Alés-Martínez ◽  
S. Hernández ◽  
R. Sánchez-Escribano ◽  
P. Aramburo
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Effective Treatment ◽  
Cancer Patients ◽  
Low Dose ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Heavily Pretreated

Real-life effectiveness of T-DM1 in heavily pretreated HER2-positive advanced breast cancer patients: An Italian observational study.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e12019-e12019 ◽  
Author(s):  
Alessandra Fabi ◽  
Katia Cannita ◽  
Gianluigi Ferretti ◽  
Mariangela Ciccarese ◽  
Grazia Arpino ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Real Life ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Life Effectiveness ◽  
Heavily Pretreated

5FU Continuous Infusion in Heavily Pretreated Advanced Breast Cancer Patients

Onkologie ◽  
2011 ◽  
Vol 34 (12) ◽  
pp. 696-700 ◽  
Author(s):  
Anne C. Regierer ◽  
Franziska Reinecke ◽  
Andrea Weigel ◽  
Annette Dieing ◽  
Silvia Lehenbauer-Dehm ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Continuous Infusion ◽  
Cancer Patients ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Heavily Pretreated

Low-Dose Aminoglutethimide Plus Steroid Replacement in Advanced Breast Cancer Patients Resistant to Conventional Therapies

1989 ◽  
Vol 7 (2) ◽  
pp. 113-116 ◽  
Author(s):  
Diana Crivellari ◽  
Enzo Galligioni ◽  
Sergio Frustaci ◽  
Giampietro Gasparini ◽  
Emanuela Vaccher ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Low Dose ◽  
Advanced Breast ◽  
Breast Cancer Patients

Efficacy and safety of docetaxel (Taxotere™) in heavily pretreated advanced breast cancer patients

1999 ◽  
Vol 35 (10) ◽  
pp. 1431-1439 ◽  
Author(s):  
J. Bonneterre ◽  
M. Spielman ◽  
J.-P. Guastalla ◽  
M. Marty ◽  
P. Viens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Advanced Breast ◽  
Efficacy And Safety ◽  
Breast Cancer Patients ◽  
Heavily Pretreated

Cisplatin and Etoposide in Chemotherapy-Refractory Advanced Breast Cancer

1988 ◽  
Vol 74 (2) ◽  
pp. 191-193 ◽  
Author(s):  
Giuseppe Giaccone ◽  
Michela Donadio ◽  
Patrizia Ferrati ◽  
Alessandro Calciati
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Advanced Breast ◽  
Nausea And Vomiting ◽  
Breast Cancer Patients ◽  
Minor Response ◽  
Heavily Pretreated ◽  
A Minor

Fourteen evaluable advanced breast cancer patients, extensively pretreated by chemotherapy, received a combination of cisplatin (DDP) and etoposide (VP 16). DDP was given at 60 or 100 mg/m2 on day 1, and VP 16 at 120 mg/m2 on days 1, 2 and 3; cycles were repeated every 4 weeks. Major responses were never obtained; a minor response in 1 patient, no change in 7 patients, and progression in 6 patients were observed. Main side effects were nausea and vomiting (62% severe), and leukopenia (31% leukocytes < 2,000/mm3). Two patients refused further treatment due to intense nausea and vomiting. DDP-VP 16 combination chemotherapy is ineffective and poorly tolerated in heavily pretreated breast cancer patients.

Mitoxantrone, 5-Fluorouracil and Low-dose Leucovorin in Doxorubicin-resistant Advanced Breast Cancer Patients: A Phase II Study

1999 ◽  
Vol 85 (6) ◽  
pp. 478-482 ◽  
Author(s):  
Snežana Šušnjar ◽  
Suzana Vasović ◽  
Zora Nešković-Konstantinović ◽  
Ljiljana Stamatović ◽  
Vesna Lukić ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Low Dose ◽  
Phase Ii Study ◽  
Advanced Breast ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document